Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 43 · Skinny Labels, Big Savings Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

35 U.S.C. § 271 Infringement of patent

+40 −4Shown
More for 35 U.S.C. § 271
Read § 271Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    by redesignating subsections (h) and (i) as subsections (k) and (l), respectively; and

  2. Carried out:

    by inserting after subsection (g) the following:(h) (1) The following shall not be acts of direct, induced, or contributory infringement of a method of use claim in a patent included in the list described in section 505(j)(7) or section 512(n)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7), 360b(n)(4)) in …

§ 271(g)–(l)

Start of § 271 to (g) unchanged ·

(1) it is materially changed by subsequent processes; or

(2) it becomes a trivial and nonessential component of another product.

(h)

(1) [inserted: The following shall not be acts of direct, induced, or contributory infringement of a method of use claim in a patent included in the list described in section 505(j)(7) or section 512(n)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7), 360b(n)(4)) in an action or counterclaim under this section:]

(A) [inserted: Submitting or seeking approval of an application under section 505(j) or section 512(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j), 360b(b)(2)), or submitting or seeking approval of an application described in section 505(b)(2) of such Act (21 U.S.C. 355(b)(2)), provided that such application includes a statement under, as applicable, section 505(j)(2)(A)(viii), section 512(n)(1)(I), or section 505(b)(2)(B) of such Act (21 U.S.C. 355(j)(2)(A)(viii), 360b(n)(1)(I), 355(b)(2)(B)) for the method of use claims in the patent with the labeling proposed in such application.]

(B) [inserted: Promoting or commercially marketing a drug product with the labeling approved in an application described in subparagraph (A).]

(C) [inserted: Describing a drug product approved in an application submitted under section 505(j) or section 512(b)(2) of such Act (21 U.S.C. 355(j), 360b(b)(2)) or approved in an application described in section 505(b)(2) of such Act (21 U.S.C. 355(b)(2)) as a generic of, or therapeutically equivalent to, the listed drug referenced in such application, as applicable.]

(2) [inserted: Subparagraphs (A) through (C) of paragraph (1) shall apply only if the labeling, promotion, or commercial marketing does not reference the condition or conditions of use claimed in the patent that was identified by the patent owner or assignee to the Secretary under section 314.53 of title 21, Code of Federal Regulations (or a successor regulation) and that was subject to the statement under section 505(j)(2)(A)(viii), section 512(n)(1)(I), or section 505(b)(2)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(2)(A)(viii), 360b(n)(1)(I), 355(b)(2)(B)), as applicable.]

(i)

(1) [inserted: The following shall not be acts of direct, induced, or contributory infringement of a patent claim covering a method of using the reference product in an action or counterclaim under this section:]

(A) [inserted: Submitting or seeking approval of an application under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)).]

(B) [inserted: Describing a biological product approved in an application described in subparagraph (A) as biosimilar to, or interchangeable with, the reference product, as applicable, with the labeling approved in such application, when the biological product has not been approved for the patented condition or conditions of use.]

(C) [inserted: Promoting or commercially marketing a biological product with the labeling approved in an application described in subparagraph (A).]

(2) [inserted: Subparagraphs (A) through (C) of paragraph (1) shall apply only if the labeling, promotion, or commercial marketing does not reference the condition or conditions of use claimed in the patent and specifically reflected in the prescribing information.]

(j) [inserted: As used in this section:]

(1) [inserted: The terms “biological product”, “biosimilar”, “interchangeable”, and “reference product” have the meanings given such terms in section 351(i) of the Public Health Service Act (42 U.S.C. 262(i)).]

(2) [inserted: The term “commercial marketing” has the meaning given such term in section 314.3 of title 21, Code of Federal Regulations (or a successor regulation).]

(3) [inserted: The term “labeling” has the meaning given such term in section 201(m) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(m)).]

(4) [inserted: The term “promoting”—]

(A) [inserted: is within the meaning of the term used in section 202.1 of title 21, Code of Federal Regulations (or a successor regulation); and]

(B) [inserted: includes the use of promotional labeling and advertising, as described in paragraphs (1) and (2) of section 202.1(l) of title 21, Code of Federal Regulations (or successor regulations).]

[struck: (h)] [inserted: (k)] As used in this section, the term “whoever” includes any State, any instrumentality of a State, and any officer or employee of a State or instrumentality of a State acting in his official capacity. Any State, and any such instrumentality, officer, or employee, shall be subject to the provisions of this title in the same manner and to the same extent as any nongovernmental entity.

[struck: (i)] [inserted: (l)] As used in this section, an “offer for sale” or an “offer to sell” by a person other than the patentee, or any designee of the patentee, is that in which the sale will occur before the expiration of the term of the patent.

Step through the changes